Table 3.
Pooled OR (95% CI) of association of CXCR4 expression with clinicopathological indicators
| clinicopathological features | No. of studies | Cases | Pooled OR (95% CI) | P | I2(%) | Effect model |
|---|---|---|---|---|---|---|
| Age (< 60 vs. ≥ 60) | 4 | 670 | 0.76(0.53–1.09) | 0.136 | 0 | Fixed |
| Sex (female vs. male) | 19 | 2208 | 1.32(1.08–1.61) | 0.006 | 13.3 | Fixed |
| Smoking history (never vs. former/current) | 4 | 589 | 1.38 (0.95–2.00) | 0.095 | 3.0 | Fixed |
| Tumor stage (T1, 2 vs. T3, 4) | 9 | 1049 | 2.34(1.28–4.28) | 0.006 | 59.0 | Random |
| Nodal stage (N0 vs. N > 0) | 16 | 1795 | 2.34(1.90–2.90) | < 0.001 | 29.4 | Fixed |
| Distant metastasis (M0 vs. M1) | 7 | 922 | 3.65 (1.53–8.68) | 0.003 | 77.7 | Random |
| Brain Metastasis (no vs. yes) | 3 | 234 | 6.45 (2.99–13.92) | < 0.001 | 5.6 | Fixed |
| Bone Metastasis (no vs. yes) | 2 | 170 | 8.00 (3.32–19.31) | < 0.001 | 0 | Fixed |
| TNM stage (I, II vs. III, IV) | 15 | 1833 | 3.10(1.95–4.93) | < 0.001 | 68.7 | Random |
| TNM stage (I vs. II) | 11 | 963 | 1.50(1.11–2.03) | 0.008 | 31.3 | Fixed |
| TNM stage (II vs. III) | 12 | 900 | 2.76(2.01–3.78) | < 0.001 | 33.0 | Fixed |
| TNM stage (III vs. IV) | 5 | 588 | 4.44(2.10–9.40) | < 0.001 | 0 | Fixed |
| Histological type (non-SCC vs. SCC) | 15 | 1829 | 1.12(0.82–1.63) | 0.405 | 54.8 | Random |
| Differentiation (well/moderate vs. poor) | 12 | 1310 | 0.90 (0.57,1.42) | 0.647 | 58.4 | Random |
| EGFR expression (low vs. high) | 3 | 264 | 2.44 (1.44,4.12) | 0.001 | 0 | Fixed |
| lymphatic vessel invasion (no vs. yes) | 3 | 401 | 1.42(0.39–5.21) | 0.599 | 88.1 | Random |
| Local recurrence (no vs. yes) | 2 | 383 | 1.18 (0.49–2.85) | 0.720 | 0 | Fixed |
OR Odds ratio, EGFR Epidermal growth factor receptor expression, SCC Squamous cell carcinoma